Survanta Market 2026 expanding neonatal respiratory care

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Survanta Market During The Forecast Period 2026–2030?

The expansion observed during the past period was a consequence of an increase in premature birth rates, heightened awareness concerning neonatal respiratory distress syndrome, the growth of neonatal intensive care units, enhanced survival rates among preterm infants, and more extensive clinical adoption of surfactant therapy.

The projected growth is driven by a greater emphasis on advanced neonatal care technologies, the expansion of neonatal healthcare access in emerging markets, ongoing clinical research in lung maturation therapies, a rising demand for early intervention treatments, and improved neonatal drug delivery methods. Concurrently, major trends anticipated during this period encompass the increasing use of surfactant replacement therapies, a growing focus on neonatal respiratory care, the global expansion of NICU infrastructure, improved administration techniques for premature infants, and enhanced clinical protocol standardization.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20302&type=smp

Which Major Factors Are Driving The Expansion Of The Survanta Market?

The survanta market is expected to see significant growth, largely driven by the rising occurrence of premature births. A premature birth occurs when an infant is born before 37 weeks of pregnancy, leading to underdeveloped organs and heightened health risks. The increasing prevalence of these early births can be attributed to factors such as advanced maternal age, various lifestyle choices, a higher incidence of chronic health conditions, and progress in fertility treatments. Survanta is employed in cases of premature births to address respiratory distress syndrome (RDS), a common condition in premature infants caused by insufficient surfactant production in their lungs, thereby aiding in improved lung function and a reduced risk of complications. For instance, in April 2025, the Centers for Disease Control and Prevention, a US-based government agency, reported that the preterm birth rate was 10.41% in 2024. Thus, the increasing frequency of premature births is a key factor propelling the expansion of the survanta market. Increasing investments in maternal and child health are anticipated to boost the growth of the survanta market in the coming years. Maternal and child health refers to the overall well-being of women during pregnancy, childbirth, and the postpartum phase, as well as the health and developmental progress of children, particularly in their early lives. The rise in these investments is driven by the necessity to lower maternal and infant mortality rates, enhance access to healthcare, and promote long-term social and economic development. Funding in maternal and child health ensures the availability of life-saving treatments like survanta, which in turn reduces neonatal mortality stemming from respiratory distress syndrome. For example, in September 2024, the American Hospital Association, a US-based professional organization, reported that the Department of Health and Human Services allocated over $558 million (USD 0.558) to initiatives focused on maternal health, including $440 million (USD 0.44) for home visiting programs and $118.5 million (USD 0.1185) for CDC programs. Consequently, growing investments in maternal and child health are fueling the expansion of the survanta market.

What Market Segments Are Evaluated Within The Survanta Market?

The survanta market covered in this report is segmented –

1) By Indication: Respiratory Distress Syndrome (RDS), Meconium Aspiration Syndrome (MAS), Bronchopulmonary Dysplasia (BPD), Acute Respiratory Failure, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Public Health Clinics

3) By End-User: Pediatric

Who Are The Top Market Participants Influencing The Survanta Market?

Major companies operating in the survanta market are AbbVie Ltd.

Read the full survanta market report here:

https://www.thebusinessresearchcompany.com/report/survanta-global-market-report

Which Region Currently Holds The Largest Share Of The Survanta Market?

North America was the largest region in the survanta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the survanta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Survanta Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20302&type=smp

Browse Through More Reports Similar to the Global Survanta Market 2026, By The Business Research Company

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Satellite Telecommunication Resellers Market Report 2026

https://www.thebusinessresearchcompany.com/report/satellite-telecommunication-resellers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795